Prognosis in multiple myeloma

  • Rafael Fonseca
  • Philip R. Greipp
Part of the Cancer Treatment and Research book series (CTAR, volume 99)


Each year nearly 15,000 patients are diagnosed with multiple myeloma in the United States alone, and most of them will die of disease progression [1]. For physicians to be able to discuss natural history with patients and tailor therapeutic modalities according to expected outcome, accurate prognostic systems are needed. Although several factors have been found to be prognostic in myeloma, there is no definitive consensus on which combination of these factors should be used. Accurate prognostication is important in everyday clinical practice as well as in the design of clinical trials. In this chapter, we will try to discuss some of the most relevant prognostic factors currently used.


Multiple Myeloma Plasma Cell Hepatocyte Growth Factor Proliferate Cell Nuclear Antigen Eastern Cooperative Oncology Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kyle RA, Beard CM, O’Fallon WM, Kurland LT. 1994. Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the trend since 1945. J Clin Oncol 12:1577–1583.PubMedGoogle Scholar
  2. 2.
    Kyle RA. 1975. Multiple myeloma: review of 869 cases. Mayo Clinic Proc 50:29–40.Google Scholar
  3. 3.
    Greipp PR, Witzig TE. 1992. Cell kinetics in plasma cell myeloma. In Manual of Clinical and Laboratory Immunology. American Society for Microbiology: Washington, D.C.Google Scholar
  4. 4.
    Greipp PR, Katzmann JA, OFallon WM, Kyle RA. 1988. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 72:219–223.PubMedGoogle Scholar
  5. 5.
    Greipp PR, Witzig TE, Gertz MA, Traynor A, Montgomery P, Morgan RJ, Katzmann JA, Kyle RA. 1990. Clinical application of cell kinetics to patients with monoclonal gammopathy and multiple myeloma. Cell Tissue Kinet 23:348.Google Scholar
  6. 6.
    Greipp PR, Lust JA, WM OF, Katzmann JA, Witzig TE, Kyle RA. 1993. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 81:3382–3387.PubMedGoogle Scholar
  7. 7.
    Boccadoro M, Marmont F, Tribalto M, et al. 1989. Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis. J Clin Oncol 7:119–125.PubMedGoogle Scholar
  8. 8.
    Boccadoro M, Marmont F, Tribalto M, et al. 1991. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 9:444–448.PubMedGoogle Scholar
  9. 9.
    Cornelissen JJ, Sonneveld P, Schoester M, Raaijmakers HG, Nieuwenhuis HK, Dekker AW, Lokhorst HM. 1994. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. J Clin Oncol 12:115–119.PubMedGoogle Scholar
  10. 10.
    Latreille J, Barlogie B, Johnston D, Drewinko B, Alexanian R. 1982. Ploidy and proliferative characteristics in monoclonal gammopathies. Blood 59:43–51.PubMedGoogle Scholar
  11. 11.
    Montecucco C, Riccardi A, Ucci G, Danova M, Carnevale R, Caporali R, Longhi M, Luoni R. 1986. Analysis of human myeloma cell population kinetics. Acta Haematol (Basel) 75:153–156.Google Scholar
  12. 12.
    Drach J, Gattringer C, Glassl H, Drach D, Huber H. 1992. The biological and clinical significance of the KI-67 growth fraction in multiple myeloma. Hematol Oncol 10:125–134.PubMedCrossRefGoogle Scholar
  13. 13.
    Girino M, Riccardi A, Luoni R, Ucci G, Cuomo A. 1991. Monoclonal antibody Ki-67 as a marker of proliferative activity in monoclonal gammopathies. Acta Haematol 85:26–30.PubMedGoogle Scholar
  14. 14.
    Ide K, Ahmann GJ, Roche PC, Greipp PR. 1992. Evaluation of a PCNA labeling index in multiple myeloma (MM). Blood 80:486a. (abstract)Google Scholar
  15. 15.
    San Miguel JF, Garcia-Sanz R, Gonzalez M, et al. 1995. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 85:448–455.Google Scholar
  16. 16.
    Trendle MC, Greipp PR, Leong T, Oken MM, Kay NE, Van Ness B, Kyle RA. 1996. Prognostic significance of the S-phase fraction of light chain restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma. Proc Am Soc Clin Oncol 15:1393a. (abstract)Google Scholar
  17. 17.
    Dewald GW, Kyle RA, Hicks GA, Greipp PR. 1985. The cinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 66:380–390.PubMedGoogle Scholar
  18. 18.
    Sawyer JR, Waldron JA, Jagannath S, Barlogie B. 1995. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 82:41–49.PubMedCrossRefGoogle Scholar
  19. 19.
    Lai JL, Zandecki M, Mary JY, Bernardi F, Izydorczyk V, Flactif M, Morel P, Jouet JP, Bauters F, Facon T. 1995. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood 85:2490–2497.PubMedGoogle Scholar
  20. 20.
    Gould J, Alexanian R, Goodacre A, Pathak S, Hecht B, Barlogie B. 1988. Plasma cell karyotype in multiple myeloma. Blood 71:453–456.PubMedGoogle Scholar
  21. 21.
    Barlogie B, Alexanian R, Dixon D, Smith L, Smallwood L, Delasalle K. 1985. Prognostic implications of tumor cell DNA and RNA content in multiple myeloma. Blood 66:338–341.PubMedGoogle Scholar
  22. 22.
    Trendle MC, Leong T, Kyle RA, Oken MM, Kay NE, Van Ness B, Greipp PR. 1997 Hypo-diploid myeloma revisited: response to therapy and survival in Eastern Cooperative Oncology Group Study E9486. Blood 88:1549a.Google Scholar
  23. 23.
    Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, Naucke S, Sawyer JR. 1995. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86:4250–4256.PubMedGoogle Scholar
  24. 24.
    Tricot G, Sawyer JR, Jagannath S, Desikan KR, Siegel D, Naucke S, Mattox S, Bracy D, Munshi N, Barlogie B. 1997. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 15:2659–2666.PubMedGoogle Scholar
  25. 25.
    Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Griepp PR, Kyle RA, Litzow MR, Gertz MA. Abnormal cytogenetics predicts for poor survival after peripheral blood stem cell transplantation in relapsed multiple myeloma. Blood 90(10):2348a.Google Scholar
  26. 26.
    Davenport RJ, Cull RE. 1992. Myeloma and benign intracranial hypertension (letter). Br Med J 304:1245–1246.CrossRefGoogle Scholar
  27. 27.
    David M, Petricoin E, Larner AC. 1996. Activation of protein kinase-A inhibits interferon induction of the JAK/STAT pathway in U266 cells. J Biol Chem 271:4585–4588.PubMedCrossRefGoogle Scholar
  28. 28.
    Davies SV, Carter C, Williams MD, Pollock A, Leeming RJ. 1992. The significance of neopterin and biopterin concentrations at presentation in haematological malignancies. Clin Lab Haematol 14:41–46.PubMedGoogle Scholar
  29. 29.
    Drach J, Schuster J, Nowotny H, et al. 1995. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res 55:3854–3859.PubMedGoogle Scholar
  30. 30.
    Fonseca R, Ahmann GJ, Juneau AL, Jalal SM, Dewald GW, Larson DM, Therneau TM, Gertz MA, Greipp PR. 1997. Cytogenetic abnormalities in multiple myeloma and related plasma cell disorders: a comparison of conventional cytogenetic analysis to fluorescent in-situ hybridization with simultaneous cytoplasmic immunoglobulin staining. Blood 90(10):1558a, p. 349, 1997. (abstract)Google Scholar
  31. 31.
    Tabernero D, San Miguel JF, Garcia-Sanz M, Najera L, Garcia-Isidoro M, Perez-Simon JA, Gonzalez M, Wiegant J, Raap AK, Orfao A. 1996. Incidence of chromosome numerical changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes. Am J Pathol 149:153–161.PubMedGoogle Scholar
  32. 32.
    Zandecki M, Lai JL, Facon T. 1996. Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol 94:217–227.PubMedCrossRefGoogle Scholar
  33. 33.
    Ahmann GJ, Jalal SM, Juneau AL, Christensen ER, Hanson CA, Dewald GW, Greipp PR. 1998. A novel three-color, clone-specific FISH procedure for monoclonal gammopathies. Cancer Genet Cytogenet. 101:7–11.PubMedCrossRefGoogle Scholar
  34. 34.
    Pérez-Simón JA, García-Sanz R, Tabernero MD, Almeida J, González M, Fernández-Calvo J, Moro MJ, Hernández JM, San Miguel JF, Orfão A. 1997. Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. Blood 90:1068a. (abstract)Google Scholar
  35. 35.
    Tricot G, Dao D, Gazitt Y, Epstein J, Sawyer J, Hooever R. 1993. Deletions of the retinoblastoma gene (Rb-1) in multiple myeloma (MM). Blood 82(Suppl 1):261a. (abstract)Google Scholar
  36. 36.
    Santhanam U, Ray A, Sehgal PB. 1991. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci U S A 88:7605–7609.PubMedCrossRefGoogle Scholar
  37. 37.
    Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM. 1996. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 88:674–681.PubMedGoogle Scholar
  38. 38.
    Vaandrager JW, Schuuring E, Zwikstra E, de Boer CJ, Kleiverda KK, van Krieken JH, Kluin-Nelemans HC, van Ommen GJ, Raap AK, Kluin PM. 1996. Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization. Blood 88:1177–1182.PubMedGoogle Scholar
  39. 39.
    Vaandrager JW, Kluin P, Schuuring E. 1997. The t(11;14) (q13;q32) in multiple myeloma cell line KMS12 has its 11q13 breakpoint 330kb centromeric from the cyclin D1 gene. Blood 89:349–350. (letter)PubMedGoogle Scholar
  40. 40.
    Neri A, Murphy JP, Cro L, Ferrero D, Tarella C, Baldini L, Dalla FR. 1989. Ras oncogene mutation in multiple myeloma. J Exp Med 170:1715–1725.PubMedCrossRefGoogle Scholar
  41. 41.
    Matozaki S, Nakagawa T, Nakao Y, Fujita T. 1991. RAS gene mutations in multiple myeloma and related monoclonal gammopathies. Kobe J Med Sci 37:35–45.PubMedGoogle Scholar
  42. 42.
    Liu P, Leong T, Quam L, Billadeau D, Kay NE, Greipp P, Kyle RA, Oken MM, Van Ness B. 1996. Activating mutations of N-and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 88:2699–2706.PubMedGoogle Scholar
  43. 43.
    Bergsagel PL, Chesi M, Brents LA, Kuehl WM. 1995. Dysregulation of c-myc in multiple myeloma — selective expression of one allele. Blood 86:222.Google Scholar
  44. 44.
    Nobuyoshi M, Kawano M, Tanaka H, Ishikawa H, Tanabe O, Iwato K, Asaoku H, Sakai A, Kuramoto A. 1991. Increased expression of the c-myc gene may be related to the aggressive transformation of human myeloma cells. Br J Haematol 77:523–528.PubMedCrossRefGoogle Scholar
  45. 45.
    Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT. 1993. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 81:128–135.PubMedGoogle Scholar
  46. 46.
    Drach J, Ackermann J, Kromer E, Fritz E, Schuster R, Gisslinger H, Zojer N, Fiegl N, Heinz R, Ludwig H, Huber H. 1997. Short survival of patients with multpile myeloma and p53 gene deletion: a study by Interphase FISH. Blood 90:244a. (abstract)Google Scholar
  47. 47.
    Greipp PR, Raymond NM, Kyle RA, OFallon WM. 1985. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood 65:305–310.PubMedGoogle Scholar
  48. 48.
    Greipp P, Leong T, Bennett JM, Gaillard JP, Klein B, Stewart JA, Oken MM, Kay NE, Van Ness B, Kyle RA. In press. Plasmablastic morphology an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9486 Report by the ECOG Myeloma Laboratory Group. Blood.Google Scholar
  49. 49.
    Bartl R. 1988. Histologie classification and staging of multiple myeloma. Hematol Oncol 6:107–113.PubMedCrossRefGoogle Scholar
  50. 50.
    Murakami H, Nemoto K, Sawamura M, et al. 1992. Prognostic relevance of morphological classification in multiple myeloma. Acta Haematol 87:113–117.PubMedGoogle Scholar
  51. 51.
    Saeed SM, Stock ND, Pohlod R, Crowley J, Salmon SE. 1991. Prognostic correlation of plasma cell acid phosphatase and beta-glucuronidase in multiple myeloma: a Southwest Oncology Group study. Blood 78:3281–3287.PubMedGoogle Scholar
  52. 52.
    Pich A, Chiusa L, Marmont F, Cappello N, Navone R. 1992. Argyrophilic nucleolar organizer region counts in multiple myeloma: a histopathological study on bone marrow trephine biopsies. Virchows Arch [A] 421:143–147.Google Scholar
  53. 53.
    Kurabayashi H, Kubota K, Shirakura T, Tamura J, Murakami H, Naruse T, Tsuchiya J. 1992. Electron microscopic analysis of myeloma cells in relation to drug response and prognosis. Ultrastruct Pathol 16:379–383.PubMedCrossRefGoogle Scholar
  54. 54.
    Anderson KC, Cochran M, Barut BA. 1989. Phenotypic and functional characterization of normal and malignant terminal B (plasma) cells. Eur J Haematol (Suppl) 51:19–26.Google Scholar
  55. 55.
    Leo R, Boeker M, Peest D, Hein R, Bartl R, Gessner JE, Selbach J, Wacker G, Deicher H. 1992. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells. Ann Hematol 64:132–139.PubMedCrossRefGoogle Scholar
  56. 56.
    Durie BG, Grogan TM. 1985. CALLA-positive myeloma: an aggressive subtype with poor survival. Blood 66:229–232.PubMedGoogle Scholar
  57. 57.
    Epstein J, Barlogie B, Katzmann J, Alexanian R. 1988. Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement. Blood 71:861–865.PubMedGoogle Scholar
  58. 58.
    San Miguel JF, Gonzalez M, Gascon A, et al. 1992. Lymphoid subsets and prognostic factors in multiple myeloma. Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol 80:305–309.PubMedGoogle Scholar
  59. 59.
    Bataille R, Vincent C, Revillard JP, Sany J. 1983. Serum beta-2-microglobulin binding activity in monoclonal gammopathy: correlative study and clinical significance. Eur J Cancer Clin Oncol 19:1075–1080.PubMedCrossRefGoogle Scholar
  60. 60.
    Bataille R, Durie BG, Grenier J. 1983. Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol 55:439–447.PubMedGoogle Scholar
  61. 61.
    Cuzick J, De SBL, Cooper EH, Chapman C, MacLennan IC. 1990. Long-term prognostic value of serum beta 2 microglobulin in myelomatosis. Br J Haematol 75:506–510.PubMedGoogle Scholar
  62. 62.
    Ortega F, Gonzalez M, Moro MJ, et al. 1992. Prognostic effect of beta 2-microglobulin in multiple myeloma. Med Clin 99:645–648.Google Scholar
  63. 63.
    Bataille R, Jourdan M, Zhang XG, Klein B. 1989. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 84:2008–2011.PubMedGoogle Scholar
  64. 64.
    Nachbaur DM, Herold M, Maneschg A, Huber H. 1991. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol 62:54–58.PubMedCrossRefGoogle Scholar
  65. 65.
    Solary E, Guiguet M, Zeller V, Casasnovas RO, Caillot D, Chavanet P, Guy H, Mack G. 1992. Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma. Am J Hematol 39:163–171.PubMedCrossRefGoogle Scholar
  66. 66.
    Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. 1992. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 80:733–737.PubMedGoogle Scholar
  67. 67.
    Greipp PR, Gaillard JP, Kalish LA, Oken MM, Miller AM, Kyle RA, Klein B. 1993. Independent prognostic value for serum soluble interleukin-6 receptor (sIL-6R) in Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9487. Proc Am Soc Clin Oncol 12:A1384, 1993.Google Scholar
  68. 68.
    Greipp PR, Gaillard JP, Klein B, Oken MM, Kalish L, Leong T, Kyle RA. 1994. Independent prognostic value for plasma cell labeling index (PCLI), immunofluorescence microscopy plasma cell percent (IMPCP), beta 2-microglobulin (B2M), soluble interleukin-6 receptor (sIL-6R), and c-reactive protein (CRP) in myeloma trial E9487 (Meeting abstract). Blood 84, 1994.Google Scholar
  69. 69.
    Cimino G, Avvisati G, Amadori S, et al. 1990. High serum IL-2 levels are predictive of prolonged survival in multiple myeloma. Br J Haematol 75:373–377.PubMedGoogle Scholar
  70. 70.
    Barlogie B, Smallwood L, Smith T, Alexanian R. 1989. High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Ann Intern Med 110:521–525.PubMedGoogle Scholar
  71. 71.
    Dimopoulos MA, Moulopoulos A, Smith T, Delasalle KB, Alexanian R. 1993. Risk of disease progression in asymptomatic multiple myeloma. Am J Med 94:57–61.PubMedCrossRefGoogle Scholar
  72. 72.
    Brown RD, Joshua DE, Ioannidis RA, Kronenberg H. 1989. Serum thymidine kinase as a marker of disease activity in patients with multiple myeloma. Aust N Z J Med 19:226–232.PubMedGoogle Scholar
  73. 73.
    Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A, Waage A, Group ftNMS. 1998. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. Blood 91:806–812.PubMedGoogle Scholar
  74. 74.
    Elomaa I, Virkkunen P, Risteli L, Risteli J. 1992. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 66:337–341.PubMedGoogle Scholar
  75. 75.
    Trendle MC, Leong T, Kyle RA, Oken MM, Kay NE, Van Ness B, Greipp PR. 1997. Measurements of serum markers of bone metabolism in patients with newly diagnosed multiple myeloma. A study from the ECOG Myeloma Clinical Trials Group. Proc Am Assoc Cancer Res 38:2163a.Google Scholar
  76. 76.
    Boccadoro M, Battaglio S, Omede P, et al. 1991. Increased serum neopterin concentration as indicator of disease severity and poor survival in multiple myeloma. Eur J Haematol 47:305–309.PubMedCrossRefGoogle Scholar
  77. 77.
    Merlini G, Perfetti V, Gobbi PG, Quaglini S, Franciotta DM, Marinone G, Ascari E. 1993. Acute phase proteins and prognosis in multiple myeloma. Br J Haematol 83:595–601.PubMedGoogle Scholar
  78. 78.
    Kaiser U, Auerbach B, Oldenburg M. 1996. The neural cell-adhesion molecule in myeloma. Leuk Lymphoma 20:389–395.PubMedCrossRefGoogle Scholar
  79. 79.
    Witzig TE, Dhodapkar MV, Kyle RA, Greipp PR. 1993. Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. Cancer 72:108–113.PubMedCrossRefGoogle Scholar
  80. 80.
    Witzig TE, Gertz MA, Lust JA, et al. 1996. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood 88:1780–1787.PubMedGoogle Scholar
  81. 81.
    Durie BG, Salmon SE. 1975. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842–854.PubMedCrossRefGoogle Scholar
  82. 82.
    Rapoport BL, Falkson HC, Falkson G. 1990. Prognostic factors affecting the survival of patients with multiple myeloma. A retrospective analysis of 86 patients. S Afr Med J 79:65–67.Google Scholar
  83. 83.
    Kay N. 1998. T-helper phenotypes in the blood of multiple myeloma patients on ECOG phase III trials E9487/E3A93. Br J Haematol 100(3):459–463.PubMedCrossRefGoogle Scholar
  84. 84.
    Oritani K, Katagiri S, Tominaga N, et al. 1990. Aberrant expression of immunoglobulin light chain isotype in B lymphocytes from patients with monoclonal gammopathies: isotypic discordance and clonal B-cell excess. Br J Haematol 75:10–14.PubMedGoogle Scholar
  85. 85.
    Osterborg A, Janson CH, Bergenbrant S, Holm G, Lefvert AK, Wigzell H, Mellstedt H. 1991. Peripheral blood T lymphocytes in patients with monoclonal gammopathies: expanded subsets as depicted by capacity to bind to autologous monoclonal immunoglobulins or reactivity with anti-V gene-restricted antibodies. Eur J Haematol 47:185–191.PubMedCrossRefGoogle Scholar
  86. 86.
    Kay NE, Oken MM, Kyle R, Van Ness B, Kalish L, Leong T, Greipp P. 1995. Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cells. Leuk Lymphoma 16:351–354.PubMedCrossRefGoogle Scholar
  87. 87.
    Kay NE, Leong T, Kyle RA, Greipp P, Billadeau D, Van Ness B, Bone N, Oken MM. 1997. Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial. Blood 90:340–345.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1999

Authors and Affiliations

  • Rafael Fonseca
  • Philip R. Greipp

There are no affiliations available

Personalised recommendations